Diana Souza de Oliveira

Diana Souza de Oliveira

Auto-generated profile, based on publicly available information

Diana Souza de Oliveira

Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
DODiana Souza de Oliveira
Diana Souza de Oliveira
MZMaykelin Fuentes Zaldívar
Maykelin Fuentes Zaldívar
AGAna Alice Maia Gonçalves
Ana Alice Maia Gonçalves
LRLucilene Aparecida Resende
Lucilene Aparecida Resende
RMReysla Maria da Silveira Mariano
Reysla Maria da Silveira Mariano
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
The development of prophylactic vaccines is important in preventing and controlling diseases such as visceral leishmaniasis (VL), in addition to being an economic measure for public health. Despite the efforts to develop a vaccine against human VL caused by Leishmania infantum, none is available, and the focus has shifted to developing vaccines against canine visceral leishmaniasis (CVL). Currently, commercially available vaccines are targeted at CVL but are not effective. Different strategies have been applied in developing and improving vaccines, such as using chimeric proteins to expand vaccine coverage. The search for patents can be a way of tracking vaccines that have the potential to be marketed. In this context, the present work presents a summary of immunological aspects relevant to VL vaccine development with a focus on the composition of chimeric protein vaccines for CVL deposited in patent banks as an important approach for biotechnological development. The resulting data could facilitate the screening and selection of antigens to compose vaccine candidates with high performance against VL.

5 October 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JLJaqueline Costa Leite
Jaqueline Costa Leite
AGAna Alice Maia Gonçalves
Ana Alice Maia Gonçalves
DODiana Souza de Oliveira
Diana Souza de Oliveira
LRLucilene Aparecida Resende
Lucilene Aparecida Resende
DBDiego Fernandes Vilas Boas
Diego Fernandes Vilas Boas
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
Dogs with visceral leishmaniasis play a key role in the transmission cycle of Leishmania infantum to humans in the urban environment. There is a consensus regarding the importance of developing a vaccine to control this disease. Despite many efforts to develop a protective vaccine against CVL, the ones currently available, Leish-tec® and LetiFend®, have limited effectiveness. This is due, in part, to the complexity of the immune response of the naturally infected dogs against the parasite and the complexity of the parasite transmission cycle. Thus, strategies, such as the development of a transmission-blocking vaccines (TBVs) already being applied to other vector-borne diseases like malaria and dengue, would be an attractive alternative to control leishmaniasis. TBVs induce the production of antibodies in the vertebrate host, which can inhibit parasite development in the vector and/or interfere with aspects of vector biology, leading to an interruption of parasite transmission. To date, there are few TBV studies for CVL and other leishmaniasis forms. However, the few studies that exist show promising results, thus justifying the further development of this approach.

14 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JLJaqueline Costa Leite
Jaqueline Costa Leite
AGAna Alice Maia Gonçalves
Ana Alice Maia Gonçalves
DODiana Souza De Oliveira
Diana Souza De Oliveira
LRLucilene Aparecida Resende
Lucilene Aparecida Resende
DBDiego Fernandes Vilas Boas
Diego Fernandes Vilas Boas
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
The dogs with canine visceral leishmaniasis (CVL) play a key role in the transmission cycle of Leishmania infantum to humans in the urban environment. There is a consensus regarding the importance of developing a vaccine to control this disease. Despite many efforts to develop a protective vaccine against CVL, the ones currently available, CaniLeish®, Leish-tec® and LetiFend® have limited effectiveness. This is due, in part, to the complexity of the immune response of the naturally infected dogs against the parasite and the complexity of the parasite transmission cycle. Thus, strategies such as the development of a transmission-blocking vaccines (TBVs), already being applied to other vector-borne diseases like malaria and dengue, would be an attractive alternative to control leishmaniasis. TBVs induce the production of antibodies in the vertebrate host, which can inhibit parasite development in the vector and/or interfere with aspects of vector biology, leading to an interruption of parasite transmission. To date, there are few TBVs studies for CVL and other leishmaniasis forms. However, the few studies that exist show promising results justifying further development of this approach.